drugset / Trial / NCT01731925
A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors
Phase 2
Unknown
44 enrolled
GERCOR - Multidisciplinary Oncology Cooperative Group
Ipsen · collabPfizer · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
Sunitinib may provide an opportunity for a novel therapeutic strategy for the treatment of subjects with neuroendocrine tumors.
Timeline
- Start
- 2013-01-07
- Primary completion
- 2017-12
- Completion
- 2017-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sunitinib | Small molecule | 37.5 mg | Oral |
| Background | Lanreotide | Other / unclassified | 120 mg | — |